MRI-guided breast biopsy based on diffusion-weighted imaging: a feasibility study
Open Access
- 30 October 2020
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 31 (5) , 2645-2656
Abstract
Objectives: This study evaluated the feasibility of DWI for lesion targeting in MRI-guided breast biopsies. Furthermore, it assessed device positioning on DWI during biopsy procedures. Methods: A total of 87 biopsy procedures (5/87 bilateral) consecutively performed between March 2019 and June 2020 were retrospectively reviewed: in these procedures, a preliminary DWI sequence (b = 1300 s/mm2) was acquired to assess lesion detectability. We included 64/87 procedures on lesions detectable at DWI; DWI sequences were added to the standard protocol to localize lesion and biopsy device and to assess the site marker correct positioning. Results: Mass lesions ranged from 5 to 48 mm, with a mean size of 10.7 mm and a median size of 8 mm. Non-mass lesions ranged from 7 to 90 mm, with a mean size of 33.9 mm and a median size of 31 mm. Positioning of the coaxial system was confirmed on both T1-weighted and DWI sequences. At DWI, the biopsy needle was detectable in 62/64 (96.9%) cases; it was not visible in 2/64 (3.1%) cases. The site marker was always identified using T1-weighted imaging; a final DWI sequence was acquired in 44/64 cases (68.8%). In 42/44 cases (95.5%), the marker was recognizable at DWI. Conclusions: DWI can be used as a cost-effective, highly reliable technique for targeting both mass and non-mass lesions, with a minimum size of 5 mm, detectable at pre-procedural DWI. DWI is also a feasible technique to localize the biopsy device and to confirm the deployment of the site marker. Key Points: • MRI-guided breast biopsy is performed in referral centers by an expert dedicated staff, based on prior MR imaging; contrast agent administration is usually needed for lesion targeting. • DWI represents a feasible, highly reliable technique for lesion targeting, avoiding contrast agent administration. • DWI allows a precise localization of both biopsy needle device and site marker.Keywords
Funding Information
- Università degli Studi di Verona
This publication has 32 references indexed in Scilit:
- Diffusion-weighted imaging of the breast—a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working groupEuropean Radiology, 2019
- Breast MRI: State of the ArtRadiology, 2019
- Breast MRI in the era of diffusion weighted imaging: do we still need signal-intensity time curves?European Radiology, 2019
- Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone ParameterInvestigative Radiology, 2018
- Accuracy of combined dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging for breast cancer detection: a meta-analysisActa Radiologica, 2015
- Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7 TEuropean Radiology, 2013
- Multicenter, Double-Blind, Randomized, Intraindividual Crossover Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine for Breast MR Imaging (DETECT Trial)Radiology, 2011
- Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working groupEuropean Journal of Cancer, 2010
- Role of Breast MRI in the Preoperative Evaluation of Patients with Newly Diagnosed Breast CancerAmerican Journal of Roentgenology, 2009
- Meta-Analysis of MR Imaging in the Diagnosis of Breast LesionsRadiology, 2008